Table 1 FDA-approved RNA-based therapies
From: RNA-based therapy in the management of lipid disorders: a review
Molecule | Approval date | Therapeutic area |
|---|---|---|
Fomivirsen [8] | 1998 | Cytomegalovirus retinitis |
Pegaptinib [9] | 2004 | Neovascular age-related macular degeneration |
Mipomersen [9] | 2013 | Familial hypercholesterolemia |
Eteplirsen [9] | 2016 | Duchenne muscular dystrophy |
Defibrotide [9] | 2016 | Hepatic veno-occlusive disease |
Patisiran [10] | 2018 | Polyneuropathy in hereditary transthyretin-mediated amyloidosis |
Givosiran [11] | 2019 | Acute hepatic porphyria |
Inclisiran [12] | 2021 | Heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease |